Zacks Research Brokers Increase Earnings Estimates for QNRX

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) – Investment analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of Quoin Pharmaceuticals in a report issued on Tuesday, May 12th. Zacks Research analyst M. Marin now expects that the company will earn ($1.83) per share for the quarter, up from their previous forecast of ($1.86). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($7.51) per share. Zacks Research also issued estimates for Quoin Pharmaceuticals’ Q3 2026 earnings at ($1.88) EPS, Q4 2026 earnings at ($1.90) EPS and FY2026 earnings at ($7.38) EPS.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.77) earnings per share for the quarter, beating the consensus estimate of ($2.17) by $0.40.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Wednesday, April 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Quoin Pharmaceuticals Price Performance

NASDAQ QNRX opened at $5.81 on Friday. The business’s fifty day moving average price is $6.89 and its 200-day moving average price is $10.27. The stock has a market capitalization of $10.46 million, a price-to-earnings ratio of -0.20 and a beta of 1.61. Quoin Pharmaceuticals has a 1-year low of $5.20 and a 1-year high of $41.80.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Quoin Pharmaceuticals by 649.6% during the fourth quarter. GAMMA Investing LLC now owns 2,084 shares of the company’s stock valued at $30,000 after purchasing an additional 1,806 shares in the last quarter. Simplify Asset Management Inc. purchased a new position in Quoin Pharmaceuticals during the fourth quarter valued at $252,000. AIGH Capital Management LLC purchased a new position in Quoin Pharmaceuticals during the fourth quarter valued at $712,000. ADAR1 Capital Management LLC purchased a new position in Quoin Pharmaceuticals during the fourth quarter valued at $840,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter worth approximately $863,000. 8.63% of the stock is currently owned by hedge funds and other institutional investors.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.